Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males.
Increasing cases of various skin diseases are key driver for the global hidradenitis suppurativa market. FDA (U.S. Food and Drug Administration) approvals for drugs and clinical trials are major factor for the growth of the market. Over the past few years, due to increasing knowledge of the disease, and introduction of new drugs and treatment options, the market is continuously growing.
The Global hidradenitis suppurativa market is growing at the CAGR of ~4.2% during the forecast period and expected to reach US$ 763.6 million by 2023.
Key Players for Global Hidradenitis suppurativa market:
Some of the key players in this market are: AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), and others
Segments:
Global Hidradenitis suppurativa market has been segmented on the basis of skin conditions which comprises of pimples, folliculitis, deep-acne, boils, and, and others. Folliculitis is further sub-segmented into bacterial folliculitis, hot tub folliculitis (pseudomonas folliculitis), barber's itch (pseudofolliculitis barbae), pityrosporum folliculitis, and others. Deep-acne is further sub-segmented into cysts, blackheads, and others. Boils are further sub-segmented into furuncle or carbuncle, cystic acne, pilondial cyst, and others.
On the basis of treatment, the market has been segmented into medications, surgery, laser treatment, Photodynamic Therapy (PDT), and others. Medication is further sub-segmented into antibiotics, antiandrogens, Immunosuppressive drugs, hormones, pain medication, Zinc supplements, sulphones, retinoids, and others. Surgery is further sub-segmented into Punch debridement, Incision and drainage, surgical removal, issue-sparing excision with electrosurgery, and others.
On the basis of end user, it is segmented into hospitals, dermatology clinics, medical research centers, academic institutes, and others.